BBB

About BBB

BBB (bbbtech.com), operating under the name MARK-B Inc., is a South Korean healthcare company established in October 2014 by CEO Jae-Gyu Choi. The firm is focused on the in-vitro and mobile diagnostics market, aiming to provide affordable, accurate, and easy-to-use diagnostic platforms for qualified labs and at-home use.

The company's core technology revolves around its patented MARK-B™ platform, which utilizes a 'Magnetic force-assisted electrochemical sandwich immunoassay' (MESIA) to quantify various biomarkers from a small blood sample. This technology enables the development of compact, portable diagnostic devices. The flagship product line includes the 'elemark®' and 'MARK-B' analyzers. The fully automated MARK-B system requires no sample pre-processing; a self-contained consumable cartridge separates plasma from whole blood and performs an electrochemical analysis, delivering results in minutes. The device features a 5.5” touchscreen, runs on Android, and offers connectivity through Wi-Fi and USB ports for data management with cloud servers and printers.

BBB's business model involves the sale of these diagnostic devices and accompanying test cartridges. The company has developed a portfolio of tests for various health conditions, including tumor markers (PSA, CEA), cardiovascular diseases (cTnI, D-dimer), sepsis, infectious diseases like COVID-19, and markers for metabolic and thyroid conditions. Significant milestones include raising $5 million in a Series A round in August 2016 and $16.5 million in a Series B round in October 2018. The company has actively formed partnerships, signing OEM contracts with firms like GreenCross MS and Philosys Inc., and has engaged in joint research with institutions such as Seoul National University Bundang Hospital and Korea University Guro Hospital to develop and validate its diagnostic kits for cancer and other chronic diseases. The company has also achieved regulatory milestones, including CE marks for its cancer and COVID-19 tests.